These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2243817)

  • 21. Advanced inoperable stomach cancer: a pilot study with the combination etoposide, adriamycin and cisplatin.
    Preusser P; Wilke H; Achterrath W; Neuhaus B; Balleisen L; Meyer J; Van de Loo J
    Anticancer Res; 1986; 6(5):1195-6. PubMed ID: 3800325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer.
    Itoh K; Sasaki Y; Fujii H; Minami H; Ohtsu T; Wakita H; Igarashi T; Watanabe Y; Onozawa Y; Kashimura M; Ohashi Y
    Clin Cancer Res; 2000 Oct; 6(10):4082-90. PubMed ID: 11051260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Control of a murine plasmacytoma with doxorubicin-cisplatin: dependence on circadian stage of treatment.
    Sothern RB; Lévi F; Haus E; Halberg F; Hrushesky WJ
    J Natl Cancer Inst; 1989 Jan; 81(2):135-45. PubMed ID: 2909754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Chemotherapy of a human pseudomyxoma peritonei transplanted in the nude mouse].
    Miyahara K
    Nihon Gan Chiryo Gakkai Shi; 1984 Jul; 19(6):1296-306. PubMed ID: 6542581
    [No Abstract]   [Full Text] [Related]  

  • 25. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice.
    Hirose A; Sato E; Fujii H; Sun B; Nishioka H; Aruoma OI
    Toxicol Appl Pharmacol; 2007 Jul; 222(2):152-8. PubMed ID: 17555784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Systemic chemotherapy with cisplatin and sodium thiosulfate (STS) rescue--its effect on the antitumor activity of cisplatin and the total platinum concentration in tumor bearing nude mice].
    Lee KE; Sawamura M; Ishibashi A; Koshiba K; Kubota T; Kawamura E
    Nihon Gan Chiryo Gakkai Shi; 1986 Apr; 21(3):601-8. PubMed ID: 3734533
    [No Abstract]   [Full Text] [Related]  

  • 27. Administration of a complex chemotherapy regimen: inpatient versus outpatient treatment.
    Pasmantier MW; Coleman M; Silver RT; Mamaril AP; Quiguyan CC; Galindo A
    Med Pediatr Oncol; 1983; 11(5):333-5. PubMed ID: 6685220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo.
    Fujimoto S; Chikazawa H
    Jpn J Cancer Res; 1998 Dec; 89(12):1343-51. PubMed ID: 10081496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
    International Collaborative Ovarian Neoplasm Group
    Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose platinum chemotherapy in advanced ovarian cancer: a phase II study.
    Bertelsen K; Bastholt L
    Gynecol Oncol; 1992 Jan; 44(1):79-82. PubMed ID: 1730430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose, short-duration cisplatin/doxorubicin combination chemotherapy for advanced ovarian epithelial cancer.
    Hunter RE; Griffin TW; Stevens S; Roman LD; Bokhari F; Reale FR; Tak WK; Fitzgerald TJ; Dillon MB; Rose PG
    Cancer; 1991 Nov; 68(9):1890-4. PubMed ID: 1655227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
    Pasmantier MW; Coleman M; Silver RT; Ballard WP
    Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor effect of oral cisplatin on certain murine tumors.
    Hasegawa Y; Morita M
    Chem Pharm Bull (Tokyo); 1985 Dec; 33(12):5511-4. PubMed ID: 3833394
    [No Abstract]   [Full Text] [Related]  

  • 34. Caffeine modulates the antitumor activity and toxic side effects of adriamycin.
    Sadzuka Y; Mochizuki E; Takino Y
    Jpn J Cancer Res; 1993 Mar; 84(3):348-53. PubMed ID: 8486534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of advanced endometrial carcinoma with cisplatin, cyclophosphamide and doxorubicin.
    Deppe G; Lin Liu T
    Acta Obstet Gynecol Scand; 1985; 64(1):83-4. PubMed ID: 4038840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Xenograft of human bronchial squamous cell carcinoma and its sensitivity to therapy].
    Bak M; Sugár J
    Orv Hetil; 1984 Dec; 125(52):3161-4, 3167. PubMed ID: 6549406
    [No Abstract]   [Full Text] [Related]  

  • 37. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group.
    Barrett RJ; Blessing JA; Homesley HD; Twiggs L; Webster KD
    Am J Clin Oncol; 1993 Dec; 16(6):494-6. PubMed ID: 8256764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transitioning historically inpatient chemotherapy regimens for hematologic malignancies to the ambulatory care setting.
    Moore DC; Arnall JR; Plesca DC
    Am J Health Syst Pharm; 2018 Nov; 75(22):1824-1830. PubMed ID: 30131323
    [No Abstract]   [Full Text] [Related]  

  • 39. Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up).
    Icli F; Akbulut H; Onur H; Yalcin B; Demirkazık A; Senler FÇ
    Breast; 2011 Apr; 20(2):155-7. PubMed ID: 20951586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.
    Lévi F; Benavides M; Chevelle C; Le Saunier F; Bailleul F; Misset JL; Regensberg C; Vannetzel JM; Reinberg A; Mathé G
    J Clin Oncol; 1990 Apr; 8(4):705-14. PubMed ID: 2179481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.